Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.


Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Table of Contents

Last Updated: September 26, 2022

Below is an overview of the sections found in the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

What’s New in the Guidelines

Guidelines Development


  • Overview of COVID-19
  • Testing for SARS-CoV-2 Infection
  • Prevention of SARS-CoV-2 Infection
  • Clinical Spectrum of SARS-CoV-2 Infection
  • Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment and Prevention of COVID-19 When There Are Logistical or Supply Constraints

Clinical Management of Adults

  • Clinical Management of Adults Summary
  • General Management of Nonhospitalized Adults With Acute COVID-19
  • Therapeutic Management of Nonhospitalized Adults With COVID-19
  • Therapeutic Management of Hospitalized Adults With COVID-19

Clinical Management of Children

  • Clinical Management of Children Summary
  • Special Considerations in Children
  • Therapeutic Management of Nonhospitalized Children With COVID-19
  • Therapeutic Management of Hospitalized Children With COVID-19
  • Therapeutic Management of Hospitalized Pediatric Patients With Multisystem Inflammatory Syndrome in Children (MIS-C) (With Discussion on Multisystem Inflammatory Syndrome in Adults [MIS-A])

Critical Care for Adults

  • Care of Critically Ill Adults With COVID-19 (Summary Recommendations)
  • Introduction to Critical Care Management of Adults With COVID-19
  • Hemodynamics for Adults
  • Oxygenation and Ventilation for Adults
  • Pharmacologic Interventions for Critically Ill Patients
  • Extracorporeal Membrane Oxygenation for Adults

Critical Care for Children

  • Introduction to Critical Care Management of Children With COVID-19
  • Hemodynamic Considerations for Children
  • Oxygenation and Ventilation for Children
  • Extracorporeal Membrane Oxygenation for Children

Antiviral Therapy

  • Antiviral Drugs That Are Approved, Authorized, or Under Evaluation for the Treatment of COVID-19 (Summary Recommendations)
  • Remdesivir
    • Table 4a. Remdesivir: Selected Clinical Data
  • Ritonavir-Boosted Nirmatrelvir (Paxlovid)
    • Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications
  • Molnupiravir
    • Interferons
      • Table 4b. Interferons: Selected Clinical Data
    • Ivermectin
      • Table 4c. Ivermectin: Selected Clinical Data
      • Table 4d. Characteristics of Antiviral Agents

      Anti-SARS-CoV-2 Antibody Products

      • Anti-SARS-CoV-2 Antibody Products (Summary Recommendations)
      • Anti-SARS-CoV-2 Monoclonal Antibodies
        • Table 5a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
      • COVID-19 Convalescent Plasma
        • Table 5b. COVID-19 Convalescent Plasma: Selected Clinical Data
      • Immunoglobulins: SARS-CoV-2 Specific
      • Table 5c. Characteristics of SARS-CoV-2 Antibody-Based Products


      • Immunomodulators Under Evaluation for the Treatment of COVID-19 (Summary Recommendations)
      • Corticosteroids
        • Table 6a. Systemic Corticosteroids: Selected Clinical Data
        • Table 6b. Inhaled Corticosteroids: Selected Clinical Data
      • Interleukin-6 Inhibitors
        • Table 6c. Interleukin-6 Inhibitors: Selected Clinical Data
      • Kinase Inhibitors: Janus Kinase Inhibitors and Bruton’s Tyrosine Kinase Inhibitors
        • Table 6d. Kinase Inhibitors: Selected Clinical Data
      • Colchicine
      • Fluvoxamine
        • Table 6e. Fluvoxamine: Selected Clinical Data
      • Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors
        • Table 6f. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data
      • Immunoglobulins: Non-SARS-CoV-2 Specific
      • Interleukin-1 Inhibitors
      • Table 6g. Characteristics of Immunomodulators

      Antithrombotic Therapy in Patients With COVID-19

      • Table 7a. Anticoagulant Therapy: Selected Clinical Data
      • Table 7b. Antiplatelet Therapy: Selected Clinical Data


      • Supplements (Summary Recommendations)
      • Vitamin C
      • Vitamin D
      • Zinc

      Considerations for Using Concomitant Medications in Patients With COVID-19

      Special Populations

      • Special Considerations in People Who Are Immunocompromised
      • Special Considerations in Adults and Children With Cancer
      • Special Considerations in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Immunotherapy Candidates, Donors, and Recipients
      • Special Considerations in Pregnancy
      • Influenza and COVID-19
      • Special Considerations in People With HIV

      Appendix A, Table 1. COVID-19 Treatment Guidelines Panel Members

      Appendix A, Table 2. COVID-19 Treatment Guidelines Panel Financial Disclosure for Companies Related to COVID-19 Treatment or Diagnostics